Three new en­ti­ties priced their pub­lic de­buts late Thurs­day and ear­ly Fri­day, in­clud­ing a SPAC, a tra­di­tion­al Nas­daq IPO and a Chi­nese biotech join­ing the Hong Kong In­dex.

Shang­hai-based Ab­bisko Ther­a­peu­tics raised the most mon­ey of the tri­umvi­rate, gar­ner­ing $226 mil­lion in its Hong Kong de­but and pric­ing at HK$12.46, or rough­ly $1.60 in US dol­lars. The blank check com­pa­ny fol­lowed up with a $150 mil­lion raise, while MiNK Ther­a­peu­tics priced on Nas­daq at $12 per share and a $40 mil­lion raise.

As the IPO mar­ket con­tin­ues to heat back up af­ter a sum­mer lull, the biotech sec­tor re­cent­ly passed the $14 bil­lion mark in com­bined funds raised, per the End­points News tal­ly. That has al­lowed the in­dus­try to re­main on pace to sur­pass last year’s record sum of $16.5 bil­lion across 91 Nas­daq de­buts, ac­cord­ing to fig­ures from the stock ex­change.

Here’s a look at each of the en­ti­ties:

Ab­bisko makes a Hong Kong de­but

Ab­bisko was found­ed in 2016 and saw sig­nif­i­cant in­vest­ment a few years lat­er from promi­nent Chi­na VC firm Qim­ing Ven­ture Part­ners.

Back in 2019, Qim­ing led the biotech’s $42 mil­lion Se­ries B round, get­ting Ab­bisko primed and ready to sub­mit its can­cer drugs for INDs. The fundraise came short­ly af­ter the biotech moved in­to Glax­o­SmithK­line’s old digs where founder Yao-Chang Xu aimed to set up a con­tract re­search ven­ture for Eli Lil­ly.

The biotech has part­nered with As­traZeneca for its lead pro­gram, a pan-FGFR in­hibitor be­ing stud­ied as a monother­a­py and in com­bi­na­tion ther­a­pies to treat urothe­lial car­ci­no­ma. Ab­bisko’s last up­date for the pro­gram came in April, when it said it would “soon” be launch­ing Phase Ib/II tri­als for the pro­gram in Chi­na.

Ab­bisko has sev­er­al oth­er FGFR-re­lat­ed pro­grams in its pipeline, in­clud­ing ones look­ing at FGFR19-pos­i­tive he­pa­to­cel­lu­lar car­ci­no­ma and oth­er sol­id tu­mors. Re­searchers are al­so work­ing on a slate of im­muno-on­col­o­gy pro­grams for things like tenosyn­ovial gi­ant cell tu­mors, graft ver­sus host dis­ease and triple neg­a­tive breast can­cer.

Fri­day’s de­but on the Hong Kong In­dex comes about nine months af­ter Ab­bisko raised $123 mil­lion in a Se­ries D round last Jan­u­ary. That round, in ad­di­tion to par­tic­i­pa­tion from Qim­ing, was led by The Car­lyle Group. Qim­ing said in a re­lease the biotech is de­but­ing with a mar­ket cap of more than $1.1 bil­lion.

An­oth­er SPAC lands on Nas­daq

The newest health­care SPAC to hit Nas­daq comes from a pair of in­vestors that raised $150 mil­lion for the en­ter­prise.

The SPAC, known as San­a­by Health Ac­qui­si­tion Corp. I, is run by San­dra Sh­pil­berg and Tim­o­thy Zan­ni. Sh­pil­berg is the founder of Seek­er Health, a dig­i­tal health­care en­roll­ment plat­form that was ac­quired by pa­tient sup­port ser­vice Ever­sana in 2018. Zan­ni, mean­while, spent 30 years at the Dutch pro­fes­sion­al ser­vices net­work KP­MG and re­tired in Sep­tem­ber 2020.

San­a­by’s S-1 con­tained much of the same boil­er­plate text used by near­ly every life sci­ences SPAC dur­ing the cur­rent boom. Its ac­qui­si­tion strat­e­gy will cen­ter around buzzy phras­es like “re­spon­si­ble in­no­va­tion” and “proven trac­tion,” with the caveat that it can still choose to re­verse-merge with a com­pa­ny from any sec­tor.

Like any SPAC, San­a­by will have two years to find a part­ner be­fore it’s re­quired to re­turn the funds to in­vestors.

Agenus spin­out set to start trad­ing

MiNK Ther­a­peu­tics comes to Nas­daq with a mod­est raise of $40 mil­lion and a lead al­lo­gene­ic nat­ur­al killer T cell ther­a­py ex­pect­ing a read­out be­fore the end of the year.

Re­searchers are study­ing the pro­gram, known as AGENT-797, in sol­id tu­mors, re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma, GvHD and ARDS re­lat­ed to Covid-19. The mul­ti­ple myelo­ma por­tion of the tri­als will like­ly read out be­fore 2021 is out, MiNK said in the S-1, while the oth­er parts come lat­er.

The GvHD study will launch some­time this quar­ter, and MiNK plans to study the pro­gram in sol­id tu­mors both as a monother­a­py and in com­bi­na­tion with check­point in­hibitors — with da­ta for both com­ing in the first half of 2022. MiNK was spun out of Agenus back in 2017, and Agenus owns an 83% stake in the com­pa­ny. MiNK will trade un­der the tick­er $INKT.

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.